Clinical Evaluation of the Nova Max Pro StatSensor device
Research type
Research Study
Full title
Clinical Evaluation of the Nova Max Pro Statsensor Point of Care Creatinine measuring device in the clinical outpatient and home setting & assessment of the patient experience
IRAS ID
289709
Contact name
Mark Harber
Contact email
Sponsor organisation
Royal Free London NHS Foundation Trust
Duration of Study in the UK
0 years, 10 months, 31 days
Research summary
Blood creatinine is an important biomarker used to monitor kidney function. In patients with chronic kidney disease or patients who have received a kidney transplant, careful and frequent monitoring of kidney function is required to enable timely intervention in the event of deteriorating kidney function. Indeed, following kidney transplantation, patients may have their blood serum creatinine checked on average 20 times, during the first year post-transplantation to monitor for graft rejection.
In current clinical practice, most blood creatinine assessments (blood tests) are undertaken in the primary care GP clinics or hospital settings. This practice places burden on healthcare resources and may delay the early detection of deteriorating kidney function. It also places additional burden on patients and impact's their lives as patients are required to attend frequent clinic appointments and undertake regular blood tests. Therefore, the ability for individuals to remotely self-monitor their own kidney function would have a number of health and socio-economic related benefits.
In the current study we evaluate the clinical usefulness and reliability of a handheld point of care creatinine monitoring device called the Nova Max Pro StatSensor device, in patients who have recently received a kidney transplant. Our aim is to compare the clinical performance (i.e accuracy and precision) of the device, with standard laboratory based measurements for measuring blood creatinine levels, in 100 transplant patients attending the outpatient clinic. All patients will be enrolled in the study for a period of 12-weeks. As part of the nested sub-study, 30 participants will measuring their creatinine levels using the Nova Max Pro StatSensor device at home, on the morning of their outpatient clinic. We assess the patients experience and attitude towards using the device via a questionnaire and structured interview at the end of the study.
REC name
North West - Greater Manchester South Research Ethics Committee
REC reference
22/NW/0323
Date of REC Opinion
17 Nov 2022
REC opinion
Further Information Favourable Opinion